Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan

1. Written informed consent must be obtained before any study specific procedures are undertaken. 2. The process of the experiment (brief describe) The patients must come back for follow during 4 to 12 weeks after starting the new therapy. The investigators will follow the patients' lipid profile and any side effects and stop the observation till 36 months after starting the new therapy. The serum level of HIV-VL, CD4, GOT, GPT, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol will be checked every 3 months. The patients' chart and all data will be delinked to protect the patients' right and privacy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV

Sex eligibility

All sexes

Study type

Observational

Primary location

Tropical medicine center

Kaohsiung City, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

HIV-infected patients who receive HAART therapy but have metabolic side effects.
Age over 20 years old

Exclusion criteria

Abnormal liver function: GOT or GPT 5 times over normal upper limit

Sponsors and collaborators

Lead sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital

Other

Registry information

Official study title

Tropical Medicine Center (TMC), Kaohsiung Medicine University Hospital (KMUH)

Important dates

Study start: 2012
Primary completion: 2017
Study completion: 2017
First posted: Oct 2, 2012
Registry last updated: Aug 9, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed